My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 703 / DOI: 10.3332/ecancer.2016.703

Conference Report

Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7–10 October 2016

After years of trials, Programmed Death Ligand and Receptor targeting finally debuts as a firstline therapy in combination and as a single agent regimen at the 2016 European Society of Medical Oncology (ESMO) Congress. The meeting brought together 20,522 attendees, from over 120 countries, to share updates and novel technologies from a wide swathe of oncology research. This year’s theme, From Disease Treatment to Patient Care, was matched by abstract presentations starting from inception of care regimens to new standards of care in high-risk patient subgroups, to wellbeing of care providers, and finally the funding obstacles at each continental level.

Keywords: ESMO, checkpoint immunotherapy, lung cancer, bladder cancer, ovarian cancer, breast cancer, CDK, fulvestrant, PD-1, PD-L1, PARP inhibition, urothelial cancer

Loading Article Metrics ... Please wait

Related videos

Related articles

Research: Circulating and tissue biomarkers in early-stage non-small cell lung cancer

Abstract | Full Article | PDF Published: 31 Jan 2017 / DOI: 10.3332/ecancer.2017.717

Policy: Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group

Abstract | Full Article | PDF | Portuguese | Spanish Published: 26 Jan 2017 / DOI: 10.3332/ecancer.2017.716

Review: Bone metastasis risk factors in breast cancer

Abstract | Full Article | PDF Published: 24 Jan 2017 / DOI: 10.3332/ecancer.2017.715

Review: Gastric cancer and related epigenetic alterations

Abstract | Full Article | PDF Published: 17 Jan 2017 / DOI: 10.3332/ecancer.2017.714

Research: The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance

Abstract | Full Article | PDF Published: 10 Jan 2017 / DOI: 10.3332/ecancer.2017.711



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence